Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 13, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Why Renal Cancer Guidelines Should be Tailored to Histologic Subtype.

Andrea Pettit1, Ali J Hajiran1, Steven C Campbell1

  • 1Department of Urology, West Virginia University School of Medicine, Morgantown, WV, USA.

European Urology Oncology
|June 11, 2026
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Letter: Minimally Invasive Partial Versus Radical Nephrectomy for cT2 RCC: A National Matched-Pair Analysis.

The Journal of urology·2026
Same author

Preoperative predictors of adverse pathology and recurrence-free survival for patients with renal masses.

BJUI compass·2026
Same author

Histologic Patterns and Germline Genetic Testing Outcomes in Presumed Sporadic Bilateral Renal Masses.

Urology practice·2026
Same author

Comparative prognostic performance of KEYNOTE-564 and AUA risk stratification in nonmetastatic clear cell renal cell carcinoma.

Urologic oncology·2025
Same author

Short- and Long-term Functional Outcomes in a Large Cohort of Partial Nephrectomy Patients Managed with Prolonged Ischemia.

Urology·2025
Same author

Renal Histotripsy and the Role of the Urologist.

The Journal of urology·2025
Same journal

Endoscopic Kidney-sparing Surgery for Upper Tract Urothelial Carcinoma: Long-term Oncological and Functional Outcomes from a Large Single-center Cohort.

European urology oncology·2026
Same journal

PROTEUS Trial the Day After: Practice Changing or Premature Escalation?

European urology oncology·2026
Same journal

Overall Survival Benefit from Metformin in High-volume Metastatic Hormone-sensitive Prostate Cancer in STAMPEDE Signals an Opportunity for Metabolically-targeted Therapies in Prostate Cancer.

European urology oncology·2026
Same journal

Dynamic Changes in Tumor Burden in Patients Undergoing PSMA RLT.

European urology oncology·2026
Same journal

Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab.

European urology oncology·2026
Same journal

PROTEUS: A Practice-changing Trial, but Are We Ready to Embrace Perioperative Apalutamide for All High-risk Patients?

European urology oncology·2026
See all related articles

Non-clear cell renal cell carcinoma (nccRCC) differs from clear cell RCC, often recurring late or in the abdomen. Current surveillance methods for nccRCC have notable strengths and weaknesses.

Area of Science:

  • Oncology
  • Urology
  • Nephrology

Background:

  • Non-clear cell renal cell carcinoma (nccRCC) exhibits distinct biological behavior compared to clear cell renal cell carcinoma (ccRCC).
  • nccRCC is associated with a higher incidence of late recurrences and abdominal relapse patterns.
  • Effective surveillance strategies are crucial for managing nccRCC post-treatment.
Keywords:
Histologic subtypeNon-clear cell renal cell carcinomaRenal cancer surveillanceRisk stratification

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Experiment Videos

Last Updated: Jun 13, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017